250 related articles for article (PubMed ID: 24999589)
1. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.
Conway K; Edmiston SN; Parker JS; Kuan PF; Tsai YH; Groben PA; Zedek DC; Scott GA; Parrish EA; Hao H; Pearlstein MV; Frank JS; Carson CC; Wilkerson MD; Zhao X; Slater NA; Moschos SJ; Ollila DW; Thomas NE
J Invest Dermatol; 2019 Jun; 139(6):1349-1361. PubMed ID: 30529013
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
Gao L; Smit MA; van den Oord JJ; Goeman JJ; Verdegaal EM; van der Burg SH; Stas M; Beck S; Gruis NA; Tensen CP; Willemze R; Peeper DS; van Doorn R
Pigment Cell Melanoma Res; 2013 Jul; 26(4):542-54. PubMed ID: 23590314
[TBL] [Abstract][Full Text] [Related]
4. DNA-methylation profiling distinguishes malignant melanomas from benign nevi.
Conway K; Edmiston SN; Khondker ZS; Groben PA; Zhou X; Chu H; Kuan PF; Hao H; Carson C; Berwick M; Olilla DW; Thomas NE
Pigment Cell Melanoma Res; 2011 Apr; 24(2):352-60. PubMed ID: 21375697
[TBL] [Abstract][Full Text] [Related]
5. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
[TBL] [Abstract][Full Text] [Related]
6. Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
Melamed RD; Aydin IT; Rajan GS; Phelps R; Silvers DN; Emmett KJ; Brunner G; Rabadan R; Celebi JT
J Invest Dermatol; 2017 Apr; 137(4):905-909. PubMed ID: 27890785
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis.
Guo Y; Long J; Lei S
J Cell Physiol; 2019 May; 234(5):7356-7367. PubMed ID: 30370527
[TBL] [Abstract][Full Text] [Related]
8. Dysplastic Nevi: Morphology and Molecular and the Controversies In-between.
Wiedemeyer K; Hartschuh W; Brenn T
Surg Pathol Clin; 2021 Jun; 14(2):341-357. PubMed ID: 34023110
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of DNA ploidy in dysplastic and Spitz nevi by flow cytometry.
Winokur TS; Palazzo JP; Johnson WC; Duray PH
J Cutan Pathol; 1990 Dec; 17(6):342-7. PubMed ID: 2074280
[TBL] [Abstract][Full Text] [Related]
10. Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives.
Albert LS; Rhodes AR; Sober AJ
J Am Acad Dermatol; 1990 Jan; 22(1):69-75. PubMed ID: 2298967
[TBL] [Abstract][Full Text] [Related]
11. Dysplastic nevus part II: Dysplastic nevi: Molecular/genetic profiles and management.
Spaccarelli N; Drozdowski R; Peters MS; Grant-Kels JM
J Am Acad Dermatol; 2023 Jan; 88(1):13-20. PubMed ID: 36252690
[TBL] [Abstract][Full Text] [Related]
12. CpG island methylator phenotype predicts progression of malignant melanoma.
Tanemura A; Terando AM; Sim MS; van Hoesel AQ; de Maat MF; Morton DL; Hoon DS
Clin Cancer Res; 2009 Mar; 15(5):1801-7. PubMed ID: 19223509
[TBL] [Abstract][Full Text] [Related]
13. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
15. Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi.
Walesch SK; Richter AM; Helmbold P; Dammann RH
Cancers (Basel); 2015 Jul; 7(3):1233-43. PubMed ID: 26198249
[TBL] [Abstract][Full Text] [Related]
16. Dermatoscopy of "dysplastic nevi": a beacon in diagnostic darkness.
Roesch A; Burgdorf W; Stolz W; Landthaler M; Vogt T
Eur J Dermatol; 2006; 16(5):479-93. PubMed ID: 17101467
[TBL] [Abstract][Full Text] [Related]
17. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
18. DNA ploidy and nuclear morphometry for the classification of dysplastic nevi.
Williams RA; Baak JP; Meijer GA; Charlton IG
Anal Quant Cytol Histol; 1999 Oct; 21(5):437-44. PubMed ID: 10560527
[TBL] [Abstract][Full Text] [Related]
19. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families.
Tucker MA; Fraser MC; Goldstein AM; Struewing JP; King MA; Crawford JT; Chiazze EA; Zametkin DP; Fontaine LS; Clark WH
Cancer; 2002 Jun; 94(12):3192-209. PubMed ID: 12115352
[TBL] [Abstract][Full Text] [Related]
20. Dysplastic nevi.
Farber MJ; Heilman ER; Friedman RJ
Dermatol Clin; 2012 Jul; 30(3):389-404. PubMed ID: 22800547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
